Metastatic Uveal Melanoma Withdrawn Phase 2 Trials for Trametinib (DB08911)

Also known as: Metastatic Malignant Uveal Melanoma / Metastatic Uveal Melanoma (UM) / Uveal Melanoma, Metastatic / Melanoma, Uveal Metastatic

IndicationStatusPhase
DBCOND0051900 (Metastatic Uveal Melanoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01328106Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal MelanomaTreatment